Overexpression of HMGB1 A-box reduced lipopolysaccharide-induced intestinal inflammation via HMGB1/TLR4 signaling in vitro

World Journal of Gastroenterology

Volumn 21, Issue 25, 2015, Pages 7764-7776

  Wang, Fu Cai ^a,b   Pei, Jing Xuan ^a   Zhu, Jun ^b   Zhou, Nan Jin ^c   Liu, Dong Sheng ^a   Xiong, Hui Fang ^a   Liu, Xiao Qun ^a   Lin, Dong Jia ^b   Xie, Yong ^a  

^a Group of intestinal disease   (China)

^b NANCHANG UNIVERSITY   (China)

^c Jiangxi Institute of Medical Science   (China)

Author keywords

Ethyl pyruvate; High mobility group box 1; HMGB1 A box; Inflammatory bowel disease; Toll like receptor 4

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; HMGB1 A BOX; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; AUTACOID; CYTOKINE; ETHYL PYRUVATE; HMGB1 PROTEIN, HUMAN; MYD88 PROTEIN, HUMAN; PYRUVIC ACID DERIVATIVE; RELA PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RELA;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; MONOCYTE; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; COCULTURE; DRUG EFFECTS; GASTROENTERITIS; GENETIC TRANSFECTION; GENETICS; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; UPREGULATION;

ANTI-INFLAMMATORY AGENTS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOKINES; GASTROENTERITIS; HMGB1 PROTEIN; HUMANS; INFLAMMATION MEDIATORS; INTESTINAL MUCOSA; LIPOPOLYSACCHARIDES; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHORYLATION; PYRUVATES; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TRANSFECTION; UP-REGULATION;

EID: 84936805396     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i25.7764     Document Type: Article

References (36)

1. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474:307-317 [PMID: 21677747 DOI: 10.1038/nature10209]
2. Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014;13:3-10 [PMID: 23774107 DOI: 10.1016/j.autrev. 2013.06.004]
3. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis 2010;16:1583-1597 [PMID: 20803699 DOI: 10.1002/ibd.21282]
4. Leal RF, Milanski M, Ayrizono Mde L, Coope A, Rodrigues VS, Portovedo M, Oliveira LM, Fagundes JJ, Coy CS, Velloso LA. Tolllike receptor 4, F4/80 and pro-inflammatory cytokines in intestinal and mesenteric fat tissue of Crohn's disease. Int J Clin Exp Med 2013;6:98-104 [PMID: 23386912]
5. Watanabe T, Higuchi K, Kobata A, Nishio H, Tanigawa T, Shiba M, Tominaga K, Fujiwara Y, Oshitani N, Asahara T, Nomoto K, Takeuchi K, Arakawa T. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 2008;57:181-187 [PMID: 17639086]
6. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. HMGB1 as a DNA-binding cytokine. J Leukoc Biol 2002;72:1084-1091 [PMID: 12488489]
7. Ju Z, Chavan SS, Antoine DJ, Dancho M, Tsaava T, Li J, Lu B, Levine YA, Stiegler A, Tamari Y, Al-Abed Y, Roth J, Tracey KJ, Yang H. Sequestering HMGB1 via DNA-conjugated beads ameliorates murine colitis. PLoS One 2014;9:e103992 [PMID: 25127031 DOI: 10.1371/journal.pone.0103992]
8. Vitali R, Palone F, Cucchiara S, Negroni A, Cavone L, Costanzo M, Aloi M, Dilillo A, Stronati L. Dipotassium Glycyrrhizate Inhibits HMGB1-Dependent Inflammation and Ameliorates Colitis in Mice. PLoS One 2013;8:e66527 [PMID: 23840500]
9. Davé SH, Tilstra JS, Matsuoka K, Li F, De Marco RA, Beer-Stolz D, Sepulveda AR, Fink MP, Lotze MT, Plevy SE. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol 2009;86:633-643 [PMID: 19454652 DOI: 10.1189/jlb.1008662]
10. Gong W, Zheng Y, Chao F, Li Y, Xu Z, Huang G, Gao X, Li S, He F. The anti-inflammatory activity of HMGB1 A box is enhanced when fused with C-terminal acidic tail. J Biomed Biotechnol 2010;2010:915234 [PMID: 20379370 DOI: 10.1155/2010/915234]
11. Gong Q, Xu JF, Yin H, Liu SF, Duan LH, Bian ZL. Protective effect of antagonist of high-mobility group box 1 on lipopolysaccharide-induced acute lung injury in mice. Scand J Immunol 2009;69:29-35 [PMID: 19140874 DOI: 10.1111/j.1365-3083.2008.02194.x]
12. Yamamoto ML, Schiestl RH. Intestinal microbiome and lymphoma development. Cancer J 2014;20:190-194 [PMID: 24855006 DOI: 10.1097/PPO.0000000000000047]
13. Xiang YT, Mei L. Research progress in pathogenesis of IBD: the role of gut flora. Sheng Li Ke Xue Jin Zhan 2013;44:247-252 [PMID: 24228514]
14. Saito K, Katakura K, Suzuki R, Suzuki T, Ohira H. Modulating Tolllike receptor 4 signaling pathway protects mice from experimental colitis. Fukushima J Med Sci 2013;59:81-88 [PMID: 24500383]
15. Chen L, Lin MJ, Zhan LL, Lv XP. Analysis of TLR4 and TLR2 polymorphisms in inflammatory bowel disease in a Guangxi Zhuang population. World J Gastroenterol 2012;18:6856-6860 [PMID: 23239925 DOI: 10.3748/wjg.v18.i46.6856]
16. Fukata M, Arditi M. The role of pattern recognition receptors in intestinal inflammation. Mucosal Immunol 2013;6:451-463 [PMID: 23515136 DOI: 10.1038/mi.2013.13]
17. Li G, Liang X, Lotze MT. HMGB1: The Central Cytokine for All Lymphoid Cells. Front Immunol 2013;4:68 [PMID: 23519706 DOI: 10.3389/fimmu.2013.00068]
18. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, Rubartelli A. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002;3:995-1001 [PMID: 12231511]
19. Wang LK, Wang LW, Li X, Han XQ, Gong ZJ. Ethyl pyruvate prevents inflammatory factors release and decreases intestinal permeability in rats with D-galactosamine-induced acute liver failure. Hepatobiliary Pancreat Dis Int 2013;12:180-188 [PMID: 23558073]
20. Entezari M, Javdan M, Antoine DJ, Morrow DM, Sitapara RA, Patel V, Wang M, Sharma L, Gorasiya S, Zur M, Wu W, Li J, Yang H, Ashby CR, Thomas D, Wang H, Mantell LL. Inhibition of extracellular HMGB1 attenuates hyperoxia-induced inflammatory acute lung injury. Redox Biol 2014;2:314-322 [PMID: 24563849 DOI: 10.1016/j.redox.2014.01.013]
21. Tang J, Deng P, Jiang Y, Tang Y, Chen B, Su L, Liu Z. Role of HMGB1 in propofol protection of rat intestinal epithelial cells injured by heat shock. Cell Biol Int 2013;37:262-266 [PMID: 23364923 DOI: 10.1002/cbin. 10040]
22. Wu CX, Sun H, Liu Q, Guo H, Gong JP. LPS induces HMGB1 relocation and release by activating the NF-κB-CBP signal transduction pathway in the murine macrophage-like cell line RAW264.7. J Surg Res 2012;175:88-100 [PMID: 21571302 DOI: 10.1016/j.jss.2011.02.026]
23. Huang W, Tang Y, Li L. HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine 2010;51:119-126 [PMID: 20347329 DOI: 10.1016/j.cyto.2010.02.021]
24. Su X, Wang H, Zhao J, Pan H, Mao L. Beneficial effects of ethyl pyruvate through inhibiting high-mobility group box 1 expression and TLR4/NF-κB pathway after traumatic brain injury in the rat. Mediators Inflamm 2011;2011:807142 [PMID: 21772666 DOI: 10.1155/2011/807142]
25. Janko C, Filipovic M, Munoz LE, Schorn C, Schett G, Ivanovic-Burmazovic I, Herrmann M. Redox modulation of HMGB1-related signaling. Antioxid Redox Signal 2014;20:1075-1085 [PMID: 23373897 DOI: 10.1089/ars.2013.5179]
26. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, Czura CJ, Fink MP, Tracey KJ. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002;99:12351-12356 [PMID: 12209006]
27. Johansson L, Snäll J, Sendi P, Linnér A, Thulin P, Linder A, Treutiger CJ, Norrby-Teglund A. HMGB1 in severe soft tissue infections caused by Streptococcus pyogenes. Front Cell Infect Microbiol 2014;4:4 [PMID: 24524027 DOI: 10.3389/fcimb.2014.00004]
28. Jia L, Clear A, Liu FT, Matthews J, Uddin N, McCarthy A, Hoxha E, Durance C, Iqbal S, Gribben JG. Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood 2014;123:1709-1719 [PMID: 24464016 DOI: 10.1182/blood-2013-10-529610]
29. Zhang CL, Shu MG, Qi HW, Li LW. Inhibition of tumor angiogenesis by HMGB1 A box peptide. Med Hypotheses 2008;70:343-345 [PMID: 17630223]
30. Le Blanc PM, Doggett TA, Choi J, Hancock MA, Durocher Y, Frank F, Nagar B, Ferguson TA, Saleh M. An immunogenic peptide in the A-box of HMGB1 protein reverses apoptosis-induced tolerance through RAGE receptor. J Biol Chem 2014;289:7777-7786 [PMID: 24474694 DOI: 10.1074/jbc. M113.541474]
31. Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, Tracey KJ, Andersson U, Harris HE. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003;48:2052-2058 [PMID: 12847700]
32. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192:565-570 [PMID: 10952726]
33. Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta 2010;1799:149-156 [PMID: 19948257 DOI: 10.1016/j.bbagrm.2009.11.019]
34. Trøseid M, Lind A, Nowak P, Barqasho B, Heger B, Lygren I, Pedersen KK, Kanda T, Funaoka H, Damås JK, Kvale D. Circulating levels of HMGB1 are correlated strongly with MD2 in HIV-infection: possible implication for TLR4-signalling and chronic immune activation. Innate Immun 2013;19:290-297 [PMID: 23070967 DOI: 10.1177/1753425912461042]
35. Maeda S, Hikiba Y, Shibata W, Ohmae T, Yanai A, Ogura K, Yamada S, Omata M. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun 2007;360:394-400 [PMID: 17599806]
36. He ZW, Qin YH, Wang ZW, Chen Y, Shen Q, Dai SM. HMGB1 acts in synergy with lipopolysaccharide in activating rheumatoid synovial fibroblasts via p38 MAPK and NF-κB signaling pathways. Mediators Inflamm 2013;2013:596716 [PMID: 24302816 DOI: 10.1155/2013/596716]